William M. Valenti, MD, FIDSA

Senior Vice President, Strategic Advancement
Trillium Health

Disclosure(s): Gilead Sciences: Grant/Research Support, Stocks/Bonds (Public Company); ViiV Healthcare: Grant/Research Support

Poster(s):

• (P-1424) Patient Experiences at Month 6 after Initiation of Cabotegravir Long-Acting (CAB LA) for PrEP in the First Male Gender Concordant Implementation Science Trial (PILLAR) in the US
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT